Updates on Genetics and Epigenetics of Haematological Malignancies: From Knowledge to Applications

Ari Melnick, MD, is the Gebroe Family Professor of Hematology/Oncology and a Professor of Medicine, Immunology and Pharmacology at Weill Cornell Medical College (WCMC) in New York City, USA. He completed a residency in internal medicine and a fellowship in hematology/oncology, as well as a postdoctoral fellowship at the Mount Sinai School of Medicine in New York City, USA.

Dr. Melnick’s research interests include the biology and molecular targeting of B-cell lymphomas and acute leukemias, targeting transcriptional and epigenetic repressors for cancer therapy, and identifying the epigenetic basis of hematologic malignancies. He and his research associates have a developed novel therapies to correct aberrant transcriptional regulation and signaling in these tumors. Dr. Melnick has authored more than 300 published manuscripts in journals such as Nature, Science, Cell, Cancer Discovery, Cancer Cell, Nature Medicine, Nature Immunology, and the New England Journal of Medicine. He is a past ASH Faculty Scholar, LLS Scholar, Burroughs Wellcome Translational Research Scholar and Kimmel Foundation Scholar and is a member of the American Society for Clinical Investigation and the American Association of Physicians. He was the Bonadonna Lecturer at the 2019 ICML meeting in Lugano and recipient of the 2020 Beutler Lecture and Prize from the American Society of Hematology. 

Dr. Melnick has been Scientific Chair of the American Society of Hematology annual meeting and chair of the AACR Lymphoma Meetings in 2018 and 2020. He also has organized a number of other international scientific meetings in the areas of epigenetics and hematologic malignancies. He has participated in numerous study sections for the NIH and other organizations, and is a member of the editorial board for journals such as Cancer Discovery and Blood Cancer Discovery.